Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

janssen-cilag s.r.o., praha array - 10707 risperidon - prášek a rozpouštědlo pro injekční suspenzi s prodlouženým uvolňováním - 25mg - risperidon

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

janssen-cilag s.r.o., praha array - 10707 risperidon - prášek a rozpouštědlo pro injekční suspenzi s prodlouženým uvolňováním - 37,5mg - risperidon

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

janssen-cilag s.r.o., praha array - 10707 risperidon - prášek a rozpouštědlo pro injekční suspenzi s prodlouženým uvolňováním - 50mg - risperidon

Slovenia - slovensk - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

johnson & johnson d.o.o. - risperidon - prašek in vehikel za suspenzijo s podaljšanim sproščanjem za injiciranje - risperidon 37,5 mg / 1 viala - risperidon

Slovenia - slovensk - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

johnson & johnson d.o.o. - risperidon - prašek in vehikel za suspenzijo s podaljšanim sproščanjem za injiciranje - risperidon 25 mg / 1 viala - risperidon

Slovenia - slovensk - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

johnson & johnson d.o.o. - risperidon - prašek in vehikel za suspenzijo s podaljšanim sproščanjem za injiciranje - risperidon 50 mg / 1 viala - risperidon

USA - engelsk - NLM (National Library of Medicine)

rebel distributors corp - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 1 mg - adults risperdal® (risperidone) is indicated for the acute and maintenance treatment of schizophrenia [see clinical studies (14.1)] . adolescents risperdal® is indicated for the treatment of schizophrenia in adolescents aged 13–17 years [see clinical studies (14.1)] . monotherapy - adults and pediatrics risperdal® is indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults and in children and adolescents aged 10–17 years [see clinical studies (14.2)] . combination therapy – adults the combination of risperdal® with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder [ see clinical studies (14.3)] . pediatrics risperdal® is indicated for the treatment of irritability associated with autistic disorder in children and adolescents aged 5–16 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods [s

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 50 mg - injection, modified release - excipient ingredients: polysorbate 20; water for injections; sodium hydroxide; dibasic sodium phosphate dihydrate; sodium chloride; citric acid; carmellose sodium - risperdal consta is indicated for the treatment of schizophrenia and related psychoses. risperdal consta is indicated for monotherapy for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar i disorder in patients with a manic or mixed episode, following stabilisation with oral risperidone. adjunctive maintenance treatment with lithium or sodium valproate in treatment refractory patients with bipolar i disorder who have at least 4 relapses in a 12 month period.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 37.5 mg - injection, modified release - excipient ingredients: citric acid; sodium chloride; carmellose sodium; polysorbate 20; dibasic sodium phosphate dihydrate; sodium hydroxide; water for injections - risperdal consta is indicated for the treatment of schizophrenia and related psychoses. risperdal consta is indicated for monotherapy for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar i disorder in patients with a manic or mixed episode, following stabilisation with oral risperidone. adjunctive maintenance treatment with lithium or sodium valproate in treatment refractory patients with bipolar i disorder who have at least 4 relapses in a 12 month period.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 25 mg - injection, modified release - excipient ingredients: sodium hydroxide; citric acid; sodium chloride; carmellose sodium; dibasic sodium phosphate dihydrate; polysorbate 20; water for injections - risperdal consta is indicated for the treatment of schizophrenia and related psychoses. risperdal consta is indicated for monotherapy for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar i disorder in patients with a manic or mixed episode, following stabilisation with oral risperidone. adjunctive maintenance treatment with lithium or sodium valproate in treatment refractory patients with bipolar i disorder who have at least 4 relapses in a 12 month period.